Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial-Onset Seizures in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
DOI:
https://doi.org/10.70749/ijbr.v3i6.1625Keywords:
Eslicarbazepine Acetate, Adjunctive therapy, Refractory partial-onset seizures, Anticonvulsants, Partial epilepsyAbstract
Background: Refractory partial-onset seizures present a significant therapeutic challenge, necessitating novel adjunctive treatments. This study aimed to evaluate the efficacy, safety, and tolerability of eslicarbazepine acetate (ESL) as an add-on therapy in adults with this condition. Methods: This was a single-center, randomized, double-blind, placebo-controlled, parallel-group trial conducted from January 2023 to December 2024. Eighty-nine adults with refractory partial-onset seizures (≥4 seizures/4 weeks despite 1–3 stable AEDs) were randomized 1:1:1 to placebo (n=30), ESL 800 mg (n=30), or ESL 1200 mg (n=29) once daily for 14 weeks after an 8-week baseline. The primary endpoint was the change in 4-week seizure frequency from baseline, analyzed using ANCOVA. Secondary endpoints included responder rates, seizure freedom, quality of life (QOLIE-31), depressive symptoms (MADRS), and adverse events. Results: Both ESL doses significantly reduced seizure frequency compared to placebo (p<0.001). LS mean change from baseline was −6.8 seizures/4 weeks (ESL 800 mg) and −8.3 seizures/4 weeks (ESL 1200 mg), versus −1.2 for placebo. Responder rates (≥50 reduction) were significantly higher with ESL (43.3% for 800 mg, 51.7% for 1200 mg) versus placebo (16.7%). Seizure freedom occurred in 10.0% (ESL 800 mg) and 13.8% (ESL 1200 mg) of patients. QOLIE-31 scores significantly improved (p<0.001), and MADRS scores decreased dose-dependently. Adverse event incidence was dose-dependent (placebo: 30.0%; ESL 800 mg: 53.3%; ESL 1200 mg: 65.5%), with common AEs including dizziness, somnolence, and diplopia. Hyponatremia occurred in 13.8% of the ESL 1200 mg group. Subgroup analysis showed superior efficacy for ESL 1200 mg in complex partial seizures and patients on two concomitant AEDs. Conclusion: ESL, at both 800 mg and 1200 mg once daily, is an effective and generally well-tolerated adjunctive therapy for adults with refractory partial-onset seizures, improving seizure control and patient-reported outcomes.
Downloads
References
Bensken, W. P., Fernandez-Baca Vaca, G., Jobst, B. C., Williams, S. M., Stange, K. C., Sajatovic, M., & Koroukian, S. M. (2021). Burden of chronic and acute conditions and symptoms in people with epilepsy. Neurology, 97(24).
https://doi.org/10.1212/wnl.0000000000012975
Guekht, A., Brodie, M., Secco, M., Li, S., Volkers, N., & Wiebe, S. (2021). The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia, 62(5), 1057-1063.
https://doi.org/10.1111/epi.16856
Adamu, A., Chen, R., Li, A., & Xue, G. (2023). Epilepsy in Asian countries. Acta Epileptologica, 5(1).
https://doi.org/10.1186/s42494-023-00136-1
Asadi-Pooya, A. A., Brigo, F., Lattanzi, S., & Blumcke, I. (2023). Adult epilepsy. The Lancet, 402(10399), 412-424.
https://doi.org/10.1016/s0140-6736(23)01048-6
Ali, A., Dindoust, D., Grant, J., & Clarke, D. (2021). Delivering epilepsy care in low-resource settings: The role of technology. Expert Review of Medical Devices, 18(sup1), 13-23.
https://doi.org/10.1080/17434440.2021.2013198
Essa, M., Gulandam, Kakar, A. U., Barech, S., Zarkon, I., Mari, S., Dawood, M., & Shah, T. (2022). Misperception about epilepsy among common public in Balochistan. Pakistan Journal of Neurological Sciences, 17(01).
https://doi.org/10.56310/pjns.v17i01.165
Patten, R. V., Austin, T. A., Cotton, E., Chan, L., Bellone, J. A., Mordecai, K., Altalib, H., Correia, S., Twamley, E. W., Jones, R. N., Sawyer, K., & LaFrance, W. C. (2024). Cognitive performance in functional seizures compared with epilepsy and healthy controls: A systematic review and meta analysis. The Lancet Psychiatry, 11(7), 516-525.
https://doi.org/10.1016/s2215-0366(24)00132-9
Tashakori-Miyanroudi, M., Souresrafil, A., Hashemi, P., Jafar Ehsanzadeh, S., Farrahizadeh, M., & Behroozi, Z. (2021). Prevalence of depression, anxiety, and psychological distress in patients with epilepsy during COVID-19: A systematic review. Epilepsy & Behavior, 125, 108410.
https://doi.org/10.1016/j.yebeh.2021.108410
Giordano, A., Siciliano, M., De Micco, R., Sant'Elia, V., Russo, A., Tedeschi, G., & Tessitore, A. (2021). Correlates of psychological distress in epileptic patients during the COVID-19 outbreak. Epilepsy & Behavior, 115, 107632.
https://doi.org/10.1016/j.yebeh.2020.107632
Mula, M., Kanner, A. M., Jetté, N., & Sander, J. W. (2021). Psychiatric comorbidities in people with epilepsy. Neurology Clinical Practice, 11(2).
https://doi.org/10.1212/cpj.0000000000000874
Wirrell, E. C. (2021). Classification of seizures and the Epilepsies. Epilepsy, 11-22.
https://doi.org/10.1002/9781119431893.ch2
Srivastav, Y., Prajapati, A., Agrahari, P., & Kumar, M. (2023). Review of the epilepsy, including its causes, symptoms, biomarkers, and management. Asian Journal of Research in Medical and Pharmaceutical Sciences, 12(4), 64-84.
https://doi.org/10.9734/ajrimps/2023/v12i4232
Ghulaxe, Y., Joshi, A., Chavada, J., Huse, S., Kalbande, B., & Sarda, P. (2023). Understanding focal seizures in adults: A comprehensive review. Cureus.
https://doi.org/10.7759/cureus.48173
Ioannou, P., Foster, D. L., Sander, J. W., Dupont, S., Gil‐Nagel, A., Drogon O'Flaherty, E., Alvarez‐Baron, E., & Medjedovic, J. (2022). The burden of epilepsy and unmet need in people with focal seizures. Brain and Behavior, 12(9).
https://doi.org/10.1002/brb3.2589
De Curtis, M., & Avoli, M. (2015). Initiation, propagation, and termination of partial (Focal) seizures. Cold Spring Harbor Perspectives in Medicine, 5(7), a022368.
https://doi.org/10.1101/cshperspect.a022368
Williamson, R., Hanif, S., Mathews, G. C., Lagrange, A. H., & Abou‐Khalil, B. (2009). Generalized‐onset seizures with secondary focal evolution. Epilepsia, 50(7), 1827-1832.
https://doi.org/10.1111/j.1528-1167.2009.02045.x
Brodovskaya, A., & Kapur, J. (2019). Circuits generating secondarily generalized seizures. Epilepsy & Behavior, 101, 106474.
https://doi.org/10.1016/j.yebeh.2019.106474
Ghosh, S., Sinha, J. K., Ghosh, S., Sharma, H., Bhaskar, R., & Narayanan, K. B. (2023). A comprehensive review of emerging trends and innovative therapies in epilepsy management. Brain Sciences, 13(9), 1305.
https://doi.org/10.3390/brainsci13091305
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021). The Pharmacoresistant epilepsy: An overview on existent and new emerging therapies. Frontiers in Neurology, 12.
https://doi.org/10.3389/fneur.2021.674483
Waris, A., Siraj, M., Khan, A., Lin, J., Asim, M., & Alhumaydh, F. A. (2024). A comprehensive overview of the current status and advancements in various treatment strategies against epilepsy. ACS Pharmacology & Translational Science, 7(12), 3729-3757.
https://doi.org/10.1021/acsptsci.4c00494
Rozensztrauch, A., & Kołtuniuk, A. (2022). The quality of life of children with epilepsy and the impact of the disease on the family functioning. International Journal of Environmental Research and Public Health, 19(4), 2277.
https://doi.org/10.3390/ijerph19042277
Yang, L., Ji, J., Lu, Q., Tang, P., Jiang, Y., Yang, H., & Tang, W. (2023). Caregivers’ experiences in the management of children with epilepsy: A systematic synthesis of qualitative studies. Seizure: European Journal of Epilepsy, 106, 117-128.
https://doi.org/10.1016/j.seizure.2023.02.004
Mecarelli, O., Di Gennaro, G., & Vigevano, F. (2022). Unmet needs and perspectives in management of drug resistant focal epilepsy: An Italian study. Epilepsy & Behavior, 137, 108950.
https://doi.org/10.1016/j.yebeh.2022.108950
Villanueva, V., Carreño, M., Gil-Nagel, A., Serrano-Castro, P. J., Serratosa, J. M., Toledo, M., Álvarez-Barón, E., Gil, A., & Subías-Labazuy, S. (2021). Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through multi-criteria decision analysis (MCDA). Epilepsy & Behavior, 122, 108222.
https://doi.org/10.1016/j.yebeh.2021.108222
Kwack, D. W., & Kim, D. W. (2023). Potential efficacy and safety of eslicarbazepine acetate oral loading in patients with epilepsy. Epilepsia, 64(9).
https://doi.org/10.1111/epi.17704
Guedes, L., Vieira, M., Gama, H., Magano, D., Fernandes, M., Calero, P., & Di Foggia, V. (2023). Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective. Epileptic Disorders, 25(6), 803-814.
https://doi.org/10.1002/epd2.20146
Leslie, T. K., Brückner, L., Chawla, S., & Brackenbury, W. J. (2020). Inhibitory effect of Eslicarbazepine acetate and S-licarbazepine on Nav1.5 channels. Frontiers in Pharmacology, 11.
https://doi.org/10.3389/fphar.2020.555047
Agbo, J., Ibrahim, Z. G., Magaji, S. Y., Mutalub, Y. B., Mshelia, P. P., & Mhya, D. H. (2023). Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy. Acta Epileptologica, 5(1).
https://doi.org/10.1186/s42494-023-00127-2
Rana, Z. S., Suman, R., Veleri, S., & Punnakkal, P. (2023). Mechanism of anti-seizure medications and emerging trends in epilepsy treatment. International Journal of Drug Discovery and Pharmacology.
https://doi.org/10.53941/ijddp.2023.100001
Kang, T., Miao, Z., Liu, S., & Ke, B. (2021). Prodrug strategies in the CNS drugs: Small modification makes big improvements. Current Topics in Medicinal Chemistry, 21(24), 2157-2169.
https://doi.org/10.2174/1568026621666210727163827
Landmark, C. J., Eyal, S., Burns, M. L., Franco, V., & Johannessen, S. I. (2023). Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring. Epileptic Disorders, 25(4), 454-471.
https://doi.org/10.1002/epd2.20069
Massot, A., Vivanco, R., Principe, A., Roquer, J., & Rocamora, R. (2014). Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: Preliminary results. Neurología (English Edition), 29(2), 94-101.
https://doi.org/10.1016/j.nrleng.2013.02.002
Banach, M., Borowicz, K. K., & Czuczwar, S. J. (2015). Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opinion on Drug Metabolism & Toxicology, 11(4), 639-648.
https://doi.org/10.1517/17425255.2015.1021686
Elger, C., Halász, P., Maia, J., Almeida, L., & Soares‐da‐Silva, P. (2009). Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study. Epilepsia, 50(3), 454-463.
https://doi.org/10.1111/j.1528-1167.2008.01946.x
Sperling, M. R., French, J., Jacobson, M. P., Pazdera, L., Gough, M., Cheng, H., ... & Zakal, K. (2016). Conversion to eslicarbazepine acetate monotherapy: a pooled analysis of 2 phase III studies. Neurology, 86(12), 1095-1102.
https://doi.org/10.1212/WNL.0000000000002497
Lattanzi, S., Brigo, F., Cagnetti, C., Verrotti, A., Zaccara, G., & Silvestrini, M. (2018). Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: An evidence-based review of efficacy, safety and place in therapy. Core Evidence, 13, 21-31.
https://doi.org/10.2147/ce.s142858
Kwan, P., & Brodie, M. J. (2000). Early identification of refractory epilepsy. New England Journal of Medicine, 342(5), 314-319.
https://doi.org/10.1056/nejm200002033420503
Sperling, M. R., Abou‐Khalil, B., Harvey, J., Rogin, J. B., Biraben, A., Galimberti, C. A., Kowacs, P. A., Hong, S. B., Cheng, H., Blum, D., Nunes, T., & Soares‐da‐Silva, P. (2014). Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial. Epilepsia, 56(2), 244-253.
https://doi.org/10.1111/epi.12894
Halász, P., Cramer, J. A., Hodoba, D., Członkowska, A., Guekht, A., Maia, J., Elger, C., Almeida, L., & Soares‐da‐Silva, P. (2010). Long‐term efficacy and safety of eslicarbazepine acetate: Results of a 1‐year open‐label extension study in partial‐onset seizures in adults with epilepsy. Epilepsia, 51(10), 1963-1969.
https://doi.org/10.1111/j.1528-1167.2010.02660.x
French, J. A., & Gazzola, D. M. (2011). New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safety? Therapeutic Advances in Drug Safety, 2(4), 141-158.
https://doi.org/10.1177/2042098611411127
Intravooth, T., Staack, A. M., Juerges, K., Stockinger, J., & Steinhoff, B. J. (2018). Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients. Epilepsy Research, 143, 7-10.
https://doi.org/10.1016/j.eplepsyres.2018.03.023
Ben‐Menachem, E., Biton, V., Jatuzis, D., Abou‐Khalil, B., Doty, P., & Rudd, G. D. (2007). Efficacy and safety of oral Lacosamide as adjunctive therapy in adults with partial‐onset seizures. Epilepsia, 48(7), 1308-1317.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
